Reduction in morbidity and mortality in secondary prevention is well supported by numerous studies as well as meta-analyses. [5] [6] [7] [8] The implementation of the therapy recommendations is seen not least in the prevalence of treatment with statins, which has been increasing for years. 9, 10 In Germany, lipid-lowering agents are reimbursed by the statutory health insurance if a cardiovascular disease (coronary heart disease), cerebrovascular disease (stroke) or peripheral arterial disease (PAD) is manifest or there is a high cardiovascular risk with an estimated probability of occurrence ≥20% in the next 10 years.
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Current US guidelines recommend increased use even in primary prevention. 12 Against the backdrop of treatment rates, which are already high and are expected to continue to increase, reliable information is needed not only about benefits, but also about possible harm from the therapy, such as increased risk of diabetes, disorders of liver and kidney functions, muscle damage, as well as the frequent occurrence of malignant diseases. 4 Here, the evidence is clearly more uncertain compared to the benefits. Since cerivastatin had to be withdrawn from the market in 2001 due to cases of lethal rhabdomyolysis, muscle damage and muscle ailments have been given greater attention as a possible side effect of the statin treatment.
Nonetheless, in Germany, there is a lack of reliable data, such as how frequently muscle disorders and muscle ailments occur. The frequency estimates of statin intolerance are scattered in the literature depending on the definition and investigation method, from 0.01% to 10%. 13 Registries and observational studies identified values from 7% to 29%. 14, 15 In clinical trials (RCTs), in contrast, there are only minor differences in the side effects compared to placebo. 16 However, experience in everyday health care seems to be different-a difference that has been seen not least in the controversy between under-reported because of methodological reasons. 20, 21 Statin treatment generally represents long-term therapy, but there are strong indications of insufficient adherence and premature discontinuation of treatment. 22, 23 Risk for non-adherence is higher in males and increases with age, comorbidities like anxiety and depression and also with reported bad news about statins [24] [25] [26] Discontinuation rates in everyday care due to side effects are higher than the rates of side effects described in clinical studies.
One reason for discontinuation of therapy or for therapy interruptions may be the occurrence of muscle pain. Studies show that patients with statin intolerance have higher rates of cardiovascular events. 27, 28 Since there is no information for Germany on the frequency of statin-associated myopathy (SAM) under everyday conditions, the goal of the study was to develop a method to report SAM based on routine data from the statutory health insurers and to make an estimate of the frequency of statin-induced myopathy based on that data. There are different definitions of SAM in the literature. 21, 29 In the following, we generally refer to any kind of muscle-related complaints with and without CK elevation. Statin-associated does not necessarily mean that there must be causality. 29 2 | MATERIALS AND METHODS
| Database
The analysis was conducted on a Germany-wide statutory health insurance (SHI) data set, the so-called "Health Care Data Informa- 
| Statin prescriptions
These are calculated in the data set based on the Anatomic-Thera- Rhabdomyolysis is not available in the German Modification. In each case, the first event with exposure is considered.
| Statin utilization pattern and SAM
Estimation of the SAM requires that the exposure time, ie, the period of treatment with statins, be determined for every statin recipient. In the SHI routine data, there is no information on the prescribed dose from which the range of coverage of the prescribed package could be determined. For this reason, the daily doses included in a package were classified for this as "days under therapy". This approach was established as a quasi-standard for the secondary data analysis of SHI routine data.
In the case of insured persons who are given a lower dose than one daily dose per day and for whom, consequently, the range of coverage of the package would be longer, when a DDD is used to calculate the range of coverage of the package, there are interruptions in therapy due to methodological reasons. This calculative ther- 
| RESULTS
Using the definition for the study population, results in 531 672
incidental statin recipients with a lipid metabolic disorder in 2010
(cf. Table 1 ). Based on the continuously insured persons as the base population in this year, the share is around 1%.
The statin recipients are described in the following initially under the three aspects: (i) Duration of prescription, (ii) Continuity of treatment and (iii) Type of therapy, ie, with or without change in the statin. In the next step, the analysis of the documentation of an SAM is made overall (according to the type of SAM) as well as according to the previously described prescription pattern.
The analysis of the prescription duration shows that roughly one quarter of the statin recipients received only a one-time prescription without a follow-up prescription in the course of the first 12 months after an incidental statin prescription. In another quarter, the therapy was ended within 364 days. Just under half of the statin recipients (49.1%), in contrast, were still treated after 365 days; 33.6% were treated continuously for 1 year. A change in statin was observed in around 14 000 incidental statin recipients in the period of 364 days after the first prescription, with such a change occurring already in more than one-third of the statin recipients within the first 91 days. In the last quarter, a statin change was observed only in just under 18%. Table 2 shows the results of the duration of therapy and continuity together with the indication of whether different statins were prescribed, ie, a "change of active substances" occurred.
| Frequency of Statin-associated Myopathy (SAM)
In the 1-year follow-up period of 531 672 incidental statin recipients, myopathy according to the included diagnoses was documented in 10 250 persons (1.93%). Myalgia (ICD 10-GM: M79.1) was documented in almost 94% of the cases (cf. Table 3 ). The specific diagnosis of "drug-induced myopathy" was given for only 58
recipients, equivalent to a share of 0.6%.
Viewed over time, the myopathy diagnosis was documented primarily in the first quarter of treatment (cf. Table 4 ). Table 6 ). This could be interpreted as an indication that a change in the active substance was made here due to complaints. Since the documentation of the outpatient diagnoses is made only on a quarterly basis, it cannot be shown whether the SAM diagnosis was documented before or on the day of prescription of another statin.
A change in the statin with subsequent discontinuation of therapy occurred in 2010 in 10 056 persons; a SAM diagnosis was coded in 416, equivalent to a share of 4.14%.
| DISCUSSION
Based on a Germany-wide data set spanning all statutory health insurance fund types, a frequency of statin-associated myopathy of treatment year and at least one statin change (5%). Consistent with other authors, 29, 33 we also see that statin therapies are continued after a change in the active substance.
T A B L E 5 Statin-associated myopathy (SAM) with categorization of incidental statin recipients and therapy end, interruptions and changes

Duration of therapy
With respect to patients who were given continuous treatment without statin changes and were diagnosed with SAM, our interpretation is that the muscle pain occurring under therapy was discussed and documented in the doctor-patient contact in the outpatient sector. A dose reduction might have been made. However, this was not able to be investigated using the available database.
If the different diagnoses that are subsumed under SAM are broken down individually, at first glance, it is confusing that "druginduced myopathy" is named as a diagnosis, and also that unspecific diagnoses are supplemented with the description "unspecified".
However, in Germany, this is consistent with the general diagnosis coding behavior in the outpatient sector. Here, the emphasis is on There are some international studies that address estimating the frequency of SAM using administrative data, 26,37-41 but they consider either only severe SAM based on hospital data (hospitalization due to SAM) or SAM restricted to rhabdomyolysis 42 and/or include laboratory values, and thus from a methodological standpoint are not comparable with the study conducted here, which observes SAM exclusively by means of diagnoses (including in the outpatient sector). Therefore, it may be assumed that in these hospital-based studies, only the most severe SAM is recorded, and the estimates of incidence rates are accordingly lower.
Chang et al. 43 also consider, in their analysis based on claims data, diagnoses from the outpatient sector, but calculate these from the plain text (myositis or rhabdomyolysis). Among 18 036 incidental statin recipients, they identified 23 cases (0.13%) with these diagnoses. These figures are around one power of ten lower than our values, which, along with possible cultural differences in the use, duration of therapy and diagnosis documentation, may also be caused by methodological differences such as the limited number of diagnoses included, the exclusion of patients with potentially interacting drugs and of patients without blood testing. Colantonio et al. 44 chose an entirely different approach which, based on administrative data, also suggested an algorithm for statin intolerance and, depending on the definition, identified a statin intolerance of 1.0% or 5.2%. The results are in the range of our study, but due to methodological differences, it has to be assumed that other patients are reported. In contrast to our approach, in their definition of statin intolerance, Colantonio et al. combined several criteria as dose reduction, switch to ezetimibe, diagnosis of rhabdomyolysis or discontinuation of therapy, "antihyperlipidemic event" after dose reduction or discontinuation of therapy or a change between three or more statins.
As our analysis of the continuity of statin therapy showed, just under half of the patients were still on therapy after 365 days; an interruption of therapy was observed in 29% (54% if one-time prescriptions are included). Data on the persistence of statin therapy have, like the estimates of the frequency of statin intolerance, a broad range. 45, 46 Zhang et al. 47 also report that in their cohort of statin recipients, an interruption of therapy was observed in 53%;
4.7% of their study patients had an indication of myalgia/myopathy.
In our study, this share was in the group of those who were not given continuous therapy and had a statin change, with 4.8% on a comparable scale.
NICE guideline 48 and expert recommendations speak of statin intolerance, even if a second statin-provided there are no signs of rhabdomyolysis-is not tolerated and there are corresponding diagnoses. 34, 35 Other causes as well as interactions as triggers must be ruled out. A subsequent discontinuation of therapy suggests intolerance. Our analysis showed that in this population, SAM was documented in around 4.2%. The available data do not include any information on the reasons for the discontinuation of therapy.
Schulman et al. 49 chose a similar approach to us in their validation study. They identified, based on ICD-9 diagnosis code, a SAM of 2.9% for patients with statins who had a change in therapy.
In our view, SAM or statin intolerance cannot necessarily be concluded from the discontinuation rates. The estimates for SAM that we calculated are conservative, since unreported dose reductions or even therapy interruptions-as specified in treatment recommendations-may occur without documentation of a diagnosis of SAM.
Even a change in the statin does not necessarily have to be associated with SAM. This may also be caused by regulatory drug policies (feedback to physicians concerning their adherence to simvastatin and pravastatin as lead compounds) or through marketing measures of pharmaceutical companies (eg, introduction of new substances, combinations or generics).
| Limitations
Some limitations must be kept in mind when interpreting the results.
Due to the database, only prescriptions that are charged to the SHI are reported, not the actual ingestion by the patient. This means that the exposure time is a result of the prescription pattern, with assumptions of the daily dose (here, 1 defined daily dose) having to be made. Statin intolerance was limited in this study to SAM using ICD-10 GM-coded inpatient and outpatient "muscle diagnoses".
These diagnoses cannot be validated externally, eg, through chart review or laboratory data. Our analysis is based on a single citation of the diagnosis. Since this is not a chronic disease (the complaints should subside after discontinuation or reducing the dose of the statins), we abstained from additional internal validation steps, such as multiple citations or citation by other, different doctor groups. We cannot rule out, that we might overestimate SAM as we did not apply a control group design. Our study design followed clinical practice, that is, the co-occurrence of incident myopathy together with incident statin use would be rated as SAM by physicians and patients in every day practice.
As a further limitation we have to mention that we did not analyze different dosages of the statins with regard to any dose effect relationship for myopathy. We lack information on the daily doses prescribed by the physician, which is a prerequisite for such an analysis.
When evaluating the results, documentation customs and billing rules (eg, diagnosis documentation to justify a CK value measurement) must be taken into account. It must also be considered that muscle pain is perceived differently according to the individual, and even physicians tolerate a CK value increase in their patients to different degrees.
| Strengths
The strengths of the study are that, as a database, the entire SHI population in Germany was made available for the first time. Based on Germany's population, only around 12% (insured privately or uninsured) were not included. An important advantage compared to clinical studies is that an unselected patient group can be observed in an everyday care setting. Without selection and recall bias and a nonresponder rate of 0%, all statin recipients can be investigated with reference to the population. Another special feature is that the documentation of the SAM was described for different populations according to their pattern of treatment and not only for patients with statin changes. Thus, it appears that the SAM frequency differs substantially.
| CONCLUSION
Compared to studies that use only hospitalizations due to SAM, the results reported here, by including the outpatient sector, also include milder cases of muscle complaints and give a realistic idea of SAM under everyday conditions. Depending on the observed pattern of treatment, the shares found in the study are between 1.3% and 5.0% and thus certainly do not represent a rare event in everyday health care. On the one hand, the results show that a not insignificant share of patients tolerate the therapy despite myalgia, since the statin therapy was continued for these patients without interruptions and without changing to an alternative statin.
On the other hand, for patients who do not tolerate statins but need them due to their cardiovascular risk profile, an alternative treatment strategy must be found. There are recommendations for approaches to this issue.
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